Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Investigator meeting · Dr. Liam Quinn

29 Aug 2026 · Virtual · Dr. Liam Quinn, Royal Marsden · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0110MI request

Capture insight from this engagement

Location: Vall d'Hebron
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Comparator checkpoint monotherapy

Scientific content used

irAE management guide

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Investigator meeting with radiation oncologist at Vall d'Hebron. Discussed sequencing after progression, comparator checkpoint monotherapy.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0110

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
10 Sept 2026, 14:47 UTC	Update	MTMei Tanaka	summary	In progress → Submitted	—	API